GlassScriptPhysician profile
Aida Grisel Casalis Calvo
NPI 1902515711
$3,803.03
in general payments reported to CMS, 2019-2025
18 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,126 · 2024: $679 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,332.81 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $674.20 | 2023-2025 | Valtoco |
| Corium, LLC | $628.08 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $233.95 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $180.44 | 2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $170.12 | 2024-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $106.08 | 2025 | Daybue |
| Catalyst Pharmaceuticals, INC. | $98.22 | 2023-2024 | Fycompa |
| Otter Pharmaceuticals, LLC | $83.12 | 2025 | Sympazan |
| Aucta Pharmaceuticals, INC. | $60.53 | 2024-2025 | Motpoly Xr |
| Tris Pharma INC | $46.02 | 2024-2025 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $39.83 | 2023 | Aptiom |
| Vertical Pharmaceuticals, LLC | $33.51 | 2025 | Relexxii |
| Sk Life Science, INC. | $30.47 | 2023 | |
| Ns Pharma, INC. | $27.48 | 2025 | Viltepso |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $19.86 | 2023 | Lyvispah |
| Biogen, INC. | $19.56 | 2023 | Spinraza |
| Noven Therapeutics, LLC | $18.75 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Casalis Calvo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.